133 related articles for article (PubMed ID: 36607947)
1. Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience.
Nguyen M; Li M; Travers A; Segelov E
Pancreas; 2022 Sep; 51(8):1007-1010. PubMed ID: 36607947
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
3. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
[TBL] [Abstract][Full Text] [Related]
4. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
Stokkel MP; Rietbergen DD; Korse CM; Taal BG
Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
[TBL] [Abstract][Full Text] [Related]
6. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: any relevance in neuroendocrine tumors?
Kidd M; Bodei L; Modlin IM
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
[TBL] [Abstract][Full Text] [Related]
11. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
13. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
14. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
Al-Risi ES; Al-Essry FS; Mula-Abed WS
Oman Med J; 2017 Sep; 32(5):365-370. PubMed ID: 29026467
[TBL] [Abstract][Full Text] [Related]
16. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.
Tomita T
Bosn J Basic Med Sci; 2020 Aug; 20(3):336-346. PubMed ID: 32020844
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
20. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
